Inhibition of nonneuronal α7-nicotinic receptor for lung cancer treatment

Laura Paleari, Eva Negri, Alessia Catassi, Michele Cilli, Denis Servent, Rolando D'Angelillo, Alfredo Cesario, Patrizia Russo, Massimo Fini

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Rationale: Studies strongly suggest that the nicotinic acetylcholine receptors for nicotine (nAChRs) play a significant role in lung cancer predisposition and natural history. The nAChR α7 subunit has been found to be pivotal in the control of nicotine-induced lung cancer development and in growth signal transduction induced by nicotine binding to nAChRs. Objectives: To investigate the anticancer effects of α7-nAChR antagonists. Methods: (1) To check the correlation between α7-nAChR presence and α-cobratoxin (α-CbT) sensitivity, binding experiments were performed in various normal human cells, lung cancer cell lines, and primary tumoral cells; (2) to demonstrate that α-CbT might be an efficient adjuvant therapy for non-small cell lung cancer (NSCLC) we expanded our previous observations to a panel of NSCLCs of various subtypes orthotopically grafted on nonobese diabetic/severe combined immunodeficient mice; (3) to gain insight into the mechanism of α-CbT-induced tumor reduction, the cells obtained after enzymatic digestion of tumors were analyzed for procaspase-9, Bax, Bad, and Bcl-XL protein; and (4) Snail/E-cadherin expression was evaluated to acquire information about the chemoresistance of cancer cells to α-CbT. Measurements and Main Results: We report herein the results of an experimental strategy aimed at investigating the antitumor effects of a powerful α7-nAChR antagonist, α-CbT, in an in vivo setting set to mimic the clinical setting of lung cancer; in addition, a possible explanation for α-CbT selectivity toward cancer cells is presented. Conclusions: We report the prolonged survival of α-CbT-treated animals in our mouse model of NSCLC, which is most likely the result of multiple mechanisms, including various antiproliferative and antiangiogenic effects.

Original languageEnglish
Pages (from-to)1141-1150
Number of pages10
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume179
Issue number12
DOIs
Publication statusPublished - Jun 15 2009

Fingerprint

Nicotinic Receptors
Lung Neoplasms
Nicotine
Non-Small Cell Lung Carcinoma
Neoplasms
bcl-X Protein
SCID Mice
Caspase 9
Cadherins
Natural History
Growth and Development
Digestion
Signal Transduction
Cell Line
Survival

Keywords

  • α7-nicotinic receptor
  • Antitumor activity
  • Apoptosis
  • Caspase-9
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Inhibition of nonneuronal α7-nicotinic receptor for lung cancer treatment. / Paleari, Laura; Negri, Eva; Catassi, Alessia; Cilli, Michele; Servent, Denis; D'Angelillo, Rolando; Cesario, Alfredo; Russo, Patrizia; Fini, Massimo.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 179, No. 12, 15.06.2009, p. 1141-1150.

Research output: Contribution to journalArticle

Paleari, Laura ; Negri, Eva ; Catassi, Alessia ; Cilli, Michele ; Servent, Denis ; D'Angelillo, Rolando ; Cesario, Alfredo ; Russo, Patrizia ; Fini, Massimo. / Inhibition of nonneuronal α7-nicotinic receptor for lung cancer treatment. In: American Journal of Respiratory and Critical Care Medicine. 2009 ; Vol. 179, No. 12. pp. 1141-1150.
@article{b6d3a5c969b040c78c00d29fa97f1f44,
title = "Inhibition of nonneuronal α7-nicotinic receptor for lung cancer treatment",
abstract = "Rationale: Studies strongly suggest that the nicotinic acetylcholine receptors for nicotine (nAChRs) play a significant role in lung cancer predisposition and natural history. The nAChR α7 subunit has been found to be pivotal in the control of nicotine-induced lung cancer development and in growth signal transduction induced by nicotine binding to nAChRs. Objectives: To investigate the anticancer effects of α7-nAChR antagonists. Methods: (1) To check the correlation between α7-nAChR presence and α-cobratoxin (α-CbT) sensitivity, binding experiments were performed in various normal human cells, lung cancer cell lines, and primary tumoral cells; (2) to demonstrate that α-CbT might be an efficient adjuvant therapy for non-small cell lung cancer (NSCLC) we expanded our previous observations to a panel of NSCLCs of various subtypes orthotopically grafted on nonobese diabetic/severe combined immunodeficient mice; (3) to gain insight into the mechanism of α-CbT-induced tumor reduction, the cells obtained after enzymatic digestion of tumors were analyzed for procaspase-9, Bax, Bad, and Bcl-XL protein; and (4) Snail/E-cadherin expression was evaluated to acquire information about the chemoresistance of cancer cells to α-CbT. Measurements and Main Results: We report herein the results of an experimental strategy aimed at investigating the antitumor effects of a powerful α7-nAChR antagonist, α-CbT, in an in vivo setting set to mimic the clinical setting of lung cancer; in addition, a possible explanation for α-CbT selectivity toward cancer cells is presented. Conclusions: We report the prolonged survival of α-CbT-treated animals in our mouse model of NSCLC, which is most likely the result of multiple mechanisms, including various antiproliferative and antiangiogenic effects.",
keywords = "α7-nicotinic receptor, Antitumor activity, Apoptosis, Caspase-9, Non-small cell lung cancer",
author = "Laura Paleari and Eva Negri and Alessia Catassi and Michele Cilli and Denis Servent and Rolando D'Angelillo and Alfredo Cesario and Patrizia Russo and Massimo Fini",
year = "2009",
month = "6",
day = "15",
doi = "10.1164/rccm.200806-908OC",
language = "English",
volume = "179",
pages = "1141--1150",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society - AJRCCM",
number = "12",

}

TY - JOUR

T1 - Inhibition of nonneuronal α7-nicotinic receptor for lung cancer treatment

AU - Paleari, Laura

AU - Negri, Eva

AU - Catassi, Alessia

AU - Cilli, Michele

AU - Servent, Denis

AU - D'Angelillo, Rolando

AU - Cesario, Alfredo

AU - Russo, Patrizia

AU - Fini, Massimo

PY - 2009/6/15

Y1 - 2009/6/15

N2 - Rationale: Studies strongly suggest that the nicotinic acetylcholine receptors for nicotine (nAChRs) play a significant role in lung cancer predisposition and natural history. The nAChR α7 subunit has been found to be pivotal in the control of nicotine-induced lung cancer development and in growth signal transduction induced by nicotine binding to nAChRs. Objectives: To investigate the anticancer effects of α7-nAChR antagonists. Methods: (1) To check the correlation between α7-nAChR presence and α-cobratoxin (α-CbT) sensitivity, binding experiments were performed in various normal human cells, lung cancer cell lines, and primary tumoral cells; (2) to demonstrate that α-CbT might be an efficient adjuvant therapy for non-small cell lung cancer (NSCLC) we expanded our previous observations to a panel of NSCLCs of various subtypes orthotopically grafted on nonobese diabetic/severe combined immunodeficient mice; (3) to gain insight into the mechanism of α-CbT-induced tumor reduction, the cells obtained after enzymatic digestion of tumors were analyzed for procaspase-9, Bax, Bad, and Bcl-XL protein; and (4) Snail/E-cadherin expression was evaluated to acquire information about the chemoresistance of cancer cells to α-CbT. Measurements and Main Results: We report herein the results of an experimental strategy aimed at investigating the antitumor effects of a powerful α7-nAChR antagonist, α-CbT, in an in vivo setting set to mimic the clinical setting of lung cancer; in addition, a possible explanation for α-CbT selectivity toward cancer cells is presented. Conclusions: We report the prolonged survival of α-CbT-treated animals in our mouse model of NSCLC, which is most likely the result of multiple mechanisms, including various antiproliferative and antiangiogenic effects.

AB - Rationale: Studies strongly suggest that the nicotinic acetylcholine receptors for nicotine (nAChRs) play a significant role in lung cancer predisposition and natural history. The nAChR α7 subunit has been found to be pivotal in the control of nicotine-induced lung cancer development and in growth signal transduction induced by nicotine binding to nAChRs. Objectives: To investigate the anticancer effects of α7-nAChR antagonists. Methods: (1) To check the correlation between α7-nAChR presence and α-cobratoxin (α-CbT) sensitivity, binding experiments were performed in various normal human cells, lung cancer cell lines, and primary tumoral cells; (2) to demonstrate that α-CbT might be an efficient adjuvant therapy for non-small cell lung cancer (NSCLC) we expanded our previous observations to a panel of NSCLCs of various subtypes orthotopically grafted on nonobese diabetic/severe combined immunodeficient mice; (3) to gain insight into the mechanism of α-CbT-induced tumor reduction, the cells obtained after enzymatic digestion of tumors were analyzed for procaspase-9, Bax, Bad, and Bcl-XL protein; and (4) Snail/E-cadherin expression was evaluated to acquire information about the chemoresistance of cancer cells to α-CbT. Measurements and Main Results: We report herein the results of an experimental strategy aimed at investigating the antitumor effects of a powerful α7-nAChR antagonist, α-CbT, in an in vivo setting set to mimic the clinical setting of lung cancer; in addition, a possible explanation for α-CbT selectivity toward cancer cells is presented. Conclusions: We report the prolonged survival of α-CbT-treated animals in our mouse model of NSCLC, which is most likely the result of multiple mechanisms, including various antiproliferative and antiangiogenic effects.

KW - α7-nicotinic receptor

KW - Antitumor activity

KW - Apoptosis

KW - Caspase-9

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=67449105739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449105739&partnerID=8YFLogxK

U2 - 10.1164/rccm.200806-908OC

DO - 10.1164/rccm.200806-908OC

M3 - Article

C2 - 19151195

AN - SCOPUS:67449105739

VL - 179

SP - 1141

EP - 1150

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 12

ER -